Literature DB >> 9422786

Identification of a Cys motif in the common beta chain of the interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 receptors essential for disulfide-linked receptor heterodimerization and activation of all three receptors.

F C Stomski1, J M Woodcock, B Zacharakis, C J Bagley, Q Sun, A F Lopez.   

Abstract

The human interleukin 3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors undergo covalent dimerization of the respective specific alpha chains with the common beta subunit (betac) in the presence of the cognate ligand. We have now performed alanine substitutions of individual Cys residues in betac to identify the Cys residues involved and their contribution to activation of the IL-3, GM-CSF, and IL-5 receptors. We found that substitution of Cys-86, Cys-91, and Cys-96 in betac but not of Cys-100 or Cys-234 abrogated disulfide-linked IL-3 receptor dimerization. However, although Cys-86 and Cys-91 betac mutants retained their ability to form non-disulfide-linked dimers with IL-3Ralpha, substitution of Cys-96 eliminated this interaction. Binding studies demonstrated that all betac mutants with the exception of C96A supported high affinity binding of IL-3 and GM-CSF. In receptor activation experiments, we found that betac mutants C86A, C91A, and C96A but not C100A or C234A abolished phosphorylation of betac in response to IL-3, GM-CSF, or IL-5. These data show that although Cys-96 is important for the structural integrity of betac, Cys-86 and Cys-91 participate in disulfide-linked receptor heterodimerization and that this linkage is essential for tyrosine phosphorylation of betac. Sequence alignment of betac with other cytokine receptor signaling subunits in light of these data shows that Cys-86 and Cys-91 represent a motif restricted to human and mouse beta chains, suggesting a unique mechanism of activation utilized by the IL-3, GM-CSF, and IL-5 receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422786     DOI: 10.1074/jbc.273.2.1192

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  The receptor that tames the innate immune response.

Authors:  Michael Brines; Anthony Cerami
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

2.  The role of interchain heterodisulfide formation in activation of the human common beta and mouse betaIL-3 receptors.

Authors:  Shamaruh Mirza; Jinglong Chen; James M Murphy; Ian G Young
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

3.  Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal.

Authors:  Sonia Salzano; Paola Checconi; Eva-Maria Hanschmann; Christopher Horst Lillig; Lucas D Bowler; Philippe Chan; David Vaudry; Manuela Mengozzi; Lucia Coppo; Sandra Sacre; Kondala R Atkuri; Bita Sahaf; Leonard A Herzenberg; Leonore A Herzenberg; Lisa Mullen; Pietro Ghezzi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-05       Impact factor: 11.205

4.  Slow-dissociation effect of common signaling subunit beta c on IL5 and GM-CSF receptor assembly.

Authors:  Tetsuya Ishino; Adrian E Harrington; Meirav Zaks-Zilberman; Jeffery J Scibek; Irwin Chaiken
Journal:  Cytokine       Date:  2008-02-21       Impact factor: 3.861

5.  Human immunodeficiency virus type 1 infection inhibits granulocyte-macrophage colony-stimulating factor-induced activation of STAT5A in human monocyte-derived macrophages.

Authors:  Tammra J Warby; Suzanne M Crowe; Anthony Jaworowski
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

6.  Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging.

Authors:  Meirav Zaks-Zilberman; Adrian E Harrington; Tetsuya Ishino; Irwin M Chaiken
Journal:  J Biol Chem       Date:  2008-03-07       Impact factor: 5.157

7.  The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities.

Authors:  Urmi Dhagat; Timothy R Hercus; Sophie E Broughton; Tracy L Nero; Karen S Cheung Tung Shing; Emma F Barry; Christy A Thomson; Steve Bryson; Emil F Pai; Barbara J McClure; John W Schrader; Angel F Lopez; Michael W Parker
Journal:  MAbs       Date:  2018-09-12       Impact factor: 5.857

8.  High yield production of a soluble human interleukin-3 variant from E. coli with wild-type bioactivity and improved radiolabeling properties.

Authors:  Timothy R Hercus; Emma F Barry; Mara Dottore; Barbara J McClure; Andrew I Webb; Angel F Lopez; Ian G Young; James M Murphy
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

Review 9.  Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care.

Authors:  Nimesh S A Patel; Kiran K Nandra; Christoph Thiemermann
Journal:  Crit Care       Date:  2012-07-26       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.